Genetic and acquired cardiac diseases are potential clinical targets for RNA interfering (RNAi) approaches, which are currently intensely being investigated. This review will give an update on ongoing RNAi treatment of cardiac diseases. Furthermore, small interfering RNA (siRNA) delivery systems, with special focus on cardiomyocyte uptake of siRNA, are discussed.